Neoadjuvant Nivolumab NSCLC: Improved Survival Rates
- Adding nivolumab (Opdivo) to chemotherapy before surgery significantly improves overall survival for adults with stage 1B to 3A resectable non-small cell lung cancer (R-NSCLC).
- Nivolumab, an anti-PD-1 antibody, enhances antitumor immunity when combined with chemotherapy.
- After a five-year follow-up, the trial's final analysis revealed a statistically significant OS benefit with neoadjuvant nivolumab and chemotherapy compared to chemotherapy alone.
Adding nivolumab to chemotherapy before surgery dramatically boosts survival rates for patients battling resectable non-small cell lung cancer (NSCLC). This is the key takeaway from the groundbreaking CheckMate 816 trial, revealing improved overall survival wiht the nivolumab and chemotherapy combination compared to chemotherapy alone. The five-year survival rate leaped to 65% in patients undergoing the combined treatment. Critically, patients achieving a pathological complete response saw an incredible 90% reduction in the risk of death. This new standard of care, reported by news Directory 3, offers new hope. Discover what’s next for innovative treatments and improved outcomes in the fight against lung cancer.
Nivolumab Plus Chemo Boosts Lung Cancer Survival Rates
Adding nivolumab (Opdivo) to chemotherapy before surgery significantly improves overall survival for adults with stage 1B to 3A resectable non-small cell lung cancer (R-NSCLC). The findings, from the CheckMate 816 trial, were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.
Nivolumab, an anti-PD-1 antibody, enhances antitumor immunity when combined with chemotherapy. This combination allows for earlier targeting of cancer cells, potentially improving overall survival (OS) rates.The CheckMate 816 trial demonstrated a median event-free survival (EFS) of 31.6 months with the combination, and 24% of patients achieved a pathological complete response. Importantly, the addition of nivolumab did not increase adverse events.
After a five-year follow-up, the trial’s final analysis revealed a statistically significant OS benefit with neoadjuvant nivolumab and chemotherapy compared to chemotherapy alone. Median OS was not reached in the nivolumab group versus 73.7 months in the chemotherapy group (HR: 0.72; P =.0479). The five-year OS rates were 65% with nivolumab and chemotherapy, compared to 55% with chemotherapy alone.
Subgroup analyses favored nivolumab with chemotherapy across various tumor PD-L1 expression levels, histologies, and baseline disease states. Exploratory analysis showed that patients with presurgical circulating tumor DNA (ctDNA) clearance had continued OS improvement across both treatment arms.
patients achieving pathological complete response (pCR) with nivolumab and chemotherapy showed sustained OS improvement compared to those not treated with nivolumab (HR: 0.11). five-year OS rates were 95% versus 56%, respectively. The five-year EFS rates were 49% versus 34%.
Patients with pCR treated with neoadjuvant nivolumab and chemotherapy had around a 90% reduction in their risk of death at 5 years compared with those without pCR.
What’s next
These findings solidify neoadjuvant nivolumab and chemotherapy as a standard of care for resectable NSCLC, marking a significant advancement in treatment strategies.